Uses
Tyrosinase 369-377, human is a HLA-A2.1-restricted epitope derived from tyrosinase, has been used to develop tumor-targeted vaccines with mixed efficacy[1][2].
References
[1] Guillaume B, et al. Analysis of the processing of seven human tumor antigens by intermediate proteasomes. J Immunol. 2012 Oct 1;189(7):3538-47. DOI:
10.4049/jimmunol.1103213[2] Mitchell MS, et al. Phase I trial of adoptive immunotherapy with cytolytic T lymphocytes immunized against a tyrosinase epitope. J Clin Oncol. 2002 Feb 15;20(4):1075-86. DOI:
10.1200/JCO.2002.20.4.1075